A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.